Reports related to this article:
Project(s): View 2 related projects in PECWeb
Plant(s): View 2 related plants in PECWeb
Released May 06, 2019 | GALWAY, IRELAND
en
Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Pharmaceutical company Allergan plc (NYSE:AGN) (Dublin, Ireland) has reaffirmed its commitment to Ireland by announcing a new investment of 65 million euro ($72.5 million) in expansion projects at two plants.
The company, best known for its Botox product, aims to expand its laboratories and manufacturing campuses at Westport in County Mayo and Clonshaugh in north Dublin. It also will add another 63 new jobs in Westport, which is the largest and most complex facility in Allergan's global network, and is responsible for the global supply of its flagship Botox as well as a range of eye care products. The Westport campus boasts a pharmaceuticals facility, two biologics plants and an ocular implant facility. Allergan employs more than 2,000 people in Ireland, more than 10% of its global workforce.
The investment in Westport focuses on four key areas: two new manufacturing suites in its biologics facility to introduce new product formats for one of its flagship products and the launch of a new product currently in development. It also will help with the completion of a state-of-the-art microbiology and cell-based laboratory. The completion of the new Biologics facility--which will cost a total of more than 140 million euro ($156 million)--is in the final stages of qualification and regulatory approval before commencing commercial production.
The company said that it is introducing automated manufacturing processes using high-end robotics at its Westport ocular implant facility. Existing manufacturing capabilities and capacity will be overhauled to cope with the introduction of new eye care products "due to launch in the coming years", the company stated.
"This 65 million-euro investment further cements Ireland's strategic role in Allergan's global network," explained Paul Coffey, vice president and plant general manager at Allergan Westport. "Continued investment of this scale builds on the 50 million-euro investment programme in 2018 and 42 million euro in 2017. We are expanding capacity to meet global demand, and we are advancing our R&D capabilities to meet the needs of the future for our business. We are proud that 40 years on we are still growing and offering valuable employment opportunities in key regions of Ireland, and we thank the communities around us for their continued support."
The investment was welcomed by Ireland's An Taoiseach Leo Varadkar: "This is great news for Westport and for Mayo and reinforces the region's deserved reputation as a location for investment and innovation. It is further evidence of the confidence international companies like Allergan continue to have in Ireland."
In Dublin, investment at the Clonshaugh facility, which encompasses two manufacturing facilities and the head office, will focus on expanding specialised manufacturing capability for new product development and the launch of new solid dose products currently in development. The facility delivers "critical small-scale pilot and manufacturing capability for Allergan's oral solid dosage product pipeline." These include products for the treatment of conditions including depression, irritable bowel syndrome, Alzheimer's disease and hypertension.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Our European headquarters are located in Galway, Ireland. Follow IIR Europe on: Facebook - Twitter - LinkedIn For more information on our European coverage send inquiries to info@industrialinfo.eu or visit us online at Industrial Info Europe.
The company, best known for its Botox product, aims to expand its laboratories and manufacturing campuses at Westport in County Mayo and Clonshaugh in north Dublin. It also will add another 63 new jobs in Westport, which is the largest and most complex facility in Allergan's global network, and is responsible for the global supply of its flagship Botox as well as a range of eye care products. The Westport campus boasts a pharmaceuticals facility, two biologics plants and an ocular implant facility. Allergan employs more than 2,000 people in Ireland, more than 10% of its global workforce.
The investment in Westport focuses on four key areas: two new manufacturing suites in its biologics facility to introduce new product formats for one of its flagship products and the launch of a new product currently in development. It also will help with the completion of a state-of-the-art microbiology and cell-based laboratory. The completion of the new Biologics facility--which will cost a total of more than 140 million euro ($156 million)--is in the final stages of qualification and regulatory approval before commencing commercial production.
The company said that it is introducing automated manufacturing processes using high-end robotics at its Westport ocular implant facility. Existing manufacturing capabilities and capacity will be overhauled to cope with the introduction of new eye care products "due to launch in the coming years", the company stated.
"This 65 million-euro investment further cements Ireland's strategic role in Allergan's global network," explained Paul Coffey, vice president and plant general manager at Allergan Westport. "Continued investment of this scale builds on the 50 million-euro investment programme in 2018 and 42 million euro in 2017. We are expanding capacity to meet global demand, and we are advancing our R&D capabilities to meet the needs of the future for our business. We are proud that 40 years on we are still growing and offering valuable employment opportunities in key regions of Ireland, and we thank the communities around us for their continued support."
The investment was welcomed by Ireland's An Taoiseach Leo Varadkar: "This is great news for Westport and for Mayo and reinforces the region's deserved reputation as a location for investment and innovation. It is further evidence of the confidence international companies like Allergan continue to have in Ireland."
In Dublin, investment at the Clonshaugh facility, which encompasses two manufacturing facilities and the head office, will focus on expanding specialised manufacturing capability for new product development and the launch of new solid dose products currently in development. The facility delivers "critical small-scale pilot and manufacturing capability for Allergan's oral solid dosage product pipeline." These include products for the treatment of conditions including depression, irritable bowel syndrome, Alzheimer's disease and hypertension.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Our European headquarters are located in Galway, Ireland. Follow IIR Europe on: Facebook - Twitter - LinkedIn For more information on our European coverage send inquiries to info@industrialinfo.eu or visit us online at Industrial Info Europe.
